(Q54570755)

1 June 2018

title

Three cheers for targeted therapy in non-small cell lung cancer... When we hit the target! (English)

1 reference

1 June 2018

author name string

Codacci-Pisanelli G

series ordinal

1

1 reference

1 June 2018

Frati L

series ordinal

2

1 reference

1 June 2018

Mini E

series ordinal

3

1 reference

1 June 2018

publication date

1 August 2011

1 reference

1 June 2018

published in

Journal of Chemotherapy

1 reference

1 June 2018

volume

23

1 reference

1 June 2018

issue

4

1 reference

1 June 2018

page(s)

245-246

1 reference

1 June 2018

FDA Oncology Committee debates Iressa's status following negative trial results

cites work

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2011.23.4.245

Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2011.23.4.245

TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2011.23.4.245

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2011.23.4.245

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2011.23.4.245

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2011.23.4.245

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2011.23.4.245

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2011.23.4.245

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2011.23.4.245

Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2011.23.4.245

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2011.23.4.245

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2011.23.4.245

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2011.23.4.245

Overcoming CYP1A1/1A2 mediated induction of metabolism by escalating erlotinib dose in current smokers

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2011.23.4.245

10.1179/JOC.2011.23.4.245

21 January 2018

Identifiers

DOI

1 reference

1 June 2018

1 reference

1 June 2018